Lupitidine (
INN; lupitidine hydrochloride (
USAN); development code SKF-93479) is a long-acting
H2 receptor antagonist[1] developed by
Smith, Kline & French and described as an
antiulcerogenic that was never marketed.[2] It was shown to inhibit nocturnal
gastric acid secretion[3] and, in experiments on rodents, produced diffuse neuroendocrine cell hyperplasia and an increase in multifocal glandular hyperplasia due to
hypergastrinemia resulting from the pharmacological suppression of gastric acid secretion.[4]
References
^Franzén L, Ghassemifar R, Malcherek P (July 1991). "Experimental mast cell activation improves connective tissue repair in the perforated rat mesentery". Agents and Actions. 33 (3–4): 371–7.
doi:
10.1007/bf01986588.
PMID1683107.
S2CID23827166.